Fei Li

Fei Li

Auto-generated profile, based on publicly available information

Fei Li

Key Laboratory of Multi-Cell Systems, Shanghai Key Laboratory of Molecular Andrology, Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, Shanghai, China

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 April 2024 in Nature
Verified
Journal Article
Closed access
PDF file
FLFei Li
Fei Li
XXXudong Xing
Xudong Xing
QJQiqi Jin
Qiqi Jin
XWXiang-Ming Wang
Xiang-Ming Wang
PDPengfei Dai
Pengfei Dai
DGDong Gao
Dong Gao

2 January 2025 in Cell Research
Verified
Journal Article
Open access
PDF file
FLFei Li
Fei Li
PDPengfei Dai
Pengfei Dai
HSHuili Shi
Huili Shi
YZYajuan Zhang
Yajuan Zhang
JHJuan He
Juan He
DGDong Gao
Dong Gao
Epigenetic regulation profoundly influences the fate of cancer cells and their capacity to switch between lineages by modulating essential gene expression, thereby shaping tumor heterogeneity and therapy response. In castration-resistant prostate cancer (CRPC), the intricacies behind androgen receptor (AR)-independent lineage plasticity remain unclear, leading to a scarcity of effective clinical treatments. Utilizing single-cell RNA sequencing on both human and mouse prostate cancer samples, combined with whole-genome bisulfite sequencing and multiple genetically engineered mouse models, we investigated the molecular mechanism of AR-independent lineage plasticity and uncovered a potential therapeutic strategy. Single-cell transcriptomic profiling of human prostate cancers, both pre- and post-androgen deprivation therapy, revealed an association between liver kinase B1 (LKB1) pathway inactivation and AR independence. LKB1 inactivation led to AR-independent lineage plasticity and global DNA hypomethylation during prostate cancer progression. Importantly, the pharmacological inhibition of TET enzymes and supplementation with S-adenosyl methionine were found to effectively suppress AR-independent prostate cancer growth. These insights shed light on the mechanism driving AR-independent lineage plasticity and propose a potential therapeutic strategy by targeting DNA hypomethylation in AR-independent CRPC.

4 November 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
LLLin L Liu
Lin L Liu
FLFei Li
Fei Li
WPWilliam Pao
William Pao
FMFranziska Michor
Franziska Michor
The advent of targeted therapy for cancer treatment has brought about a paradigm shift in the clinical management of human malignancies. Agents such as erlotinib used for EGFR-mutant non-small cell lung cancer or imatinib for chronic myeloid leukemia, for instance, lead to rapid tumor responses. Unfortunately, however, resistance often emerges and renders these agents ineffective after a variable amount of time. The FDA-approved dosing schedules for these drugs were not designed to optimally prevent the emergence of resistance. To this end, we have previously utilized evolutionary mathematical modeling of treatment responses to elucidate the dosing schedules best able to prevent or delay the onset of resistance. Here we expand on our approaches by taking into account dose-dependent mutation rates at which resistant cells emerge. The relationship between the serum drug concentration and the rate at which resistance mutations arise can lead to non-intuitive results about the best dose administration strategies to prevent or delay the emergence of resistance. We used mathematical modeling, available clinical trial data, and different considerations of the relationship between mutation rate and drug concentration to predict the effectiveness of different dosing strategies. We designed several distinct measures to interrogate the effects of different treatment dosing strategies and found that a low-dose continuous strategy coupled with high-dose pulses leads to the maximal delay until clinically observable resistance. Furthermore, the response to treatment is robust against different assumptions of the mutation rate as a function of drug concentration. For new and existing targeted drugs, our methodology can be employed to compare the effectiveness of different dose administration schedules and investigate the influence of changing mutation rates on outcomes.

29 October 2003 in Analytical Chemistry
Verified
Journal Article
Closed access
YCYong Chen
Yong Chen
ZGZhao Gao
Zhao Gao
FLFei Li
Fei Li
LGLiaohai Ge
Liaohai Ge
MZMeiqin Zhang
Meiqin Zhang
YSYuanhua Shao
Yuanhua Shao

18 June 2024 in Nature
Verified
Journal Article
Open access
PDF file
FLFei Li
Fei Li
XXXudong Xing
Xudong Xing
QJQiqi Jin
Qiqi Jin
XWXiang-Ming Wang
Xiang-Ming Wang
PDPengfei Dai
Pengfei Dai
DGDong Gao
Dong Gao

18 March 2025 in Cell Research
Verified
Journal Article
Open access
PDF file
FLFei Li
Fei Li
PDPengfei Dai
Pengfei Dai
HSHuili Shi
Huili Shi
YZYajuan Zhang
Yajuan Zhang
JHJuan He
Juan He
DGDong Gao
Dong Gao